The agreement grants to Heska broad rights to market the product in the companion animal health market.
Financial terms of the agreement were not disclosed. The product is being designed for use marketing single product both dogs and cats, and is expected to be introduced by Heska next year following regulatory approval.
The diseases can cause severe intestinal problems, diarrhea, reduced food intake and malnutrition. Furthermore, both of these infections are of concern because of the potential marketing single product be transmitted to people. Veterinarians need new products that can provide a rapid and accurate diagnosis of these diseases.
We know of no single product currently being marketed which can provide point-of-care diagnosis of these two infections in companion animals, and we believe that our product will meet that need.
Heska has a sophisticated scientific effort devoted to applying biotechnology to the large and growing companion animal health market. Heska's existing state-of-the-art allergy diagnostics and immunotherapy products are sold to veterinarians for the testing and treatment of thousands of allergic cats and dogs each year. Heska also offers diagnostic and patient monitoring instrumentation and supplies, as well as pharmaceuticals, vaccines and diagnostic products in the United States and Europe to veterinarians, and operates a USDA- and FDA-licensed facility, which manufactures vaccines and pharmaceutical products.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Heska to be materially different from any future results, performance or achievements seriöse partnervermittlung thailand or implied by such forward-looking statements.
Heska's achievement of these results may be affected by many factors, including among others, the following: uncertainties regarding the regulatory approval of products prior to market introduction, uncertainties regarding the outcome of research and product development efforts by Heska and by others, uncertainties regarding the outcome of sales and marketing efforts by Heska and by others or marketing single product ability to successfully commercialise products in both the U.